2018 | |
---|---|
Criterium: | Position: |
Overall Score: | > 1000 |
Total Project Funding per Partner: | 500-600 |
Total Number of Projects: | > 1000 |
Networking Rank (Reputation): | > 1000 |
2012 | |
Criterium: | Position: |
Overall Score: | > 1000 |
Networking Rank (Reputation): | > 1000 |
Networking Rank (Reputation): | > 1000 |
Total number of projects: 5
As coordinator: 0
As participant: 5
Sole participant: 0
Coordinator / Participant Ratio: 0*
Total project funding [€]: | Projects [No]: | |||||
---|---|---|---|---|---|---|
Year: | coordinator* | participant* | per partner | as coordinator | as participant | |
2021 | 0 | 6.000.000 | 112.118 | 1 | ||
2018 | 0 | 6.013.749 | 2.501.250 | 1 | ||
2017 | 0 | 5.792.425 | 1.561.250 | 1 | ||
2013 | 0 | 5.995.080 | 1.199.016 | 1 | ||
2012 | 0 | 5.990.236 | 599.024 | 1 |
Total number of partners: 38
Partner loyalty:
Frequent Partner: (> 2 projects): 0
Rare Partner: 38
Frequent / Rare Partner Ratio: 0
Start date | Project | acronym | role | funding | partners |
---|---|---|---|---|---|
2021-06-01 | Using real-world big data from eHealth, biobanks and national registries, integrated with clinical trial data to improve outcome of severe mental disorders | REALMENT | participant | 6.000.000 | 15 |
2018-01-01 | A pivotal phase IIb clinical trial of inhaled alginate oligosaccharide (OligoG) for cystic fibrosis | OligoGpivotalCF | participant | 6.013.749 | 6 |
2017-12-01 | Soraprazan - a new regenerative therapy for Stargardt's disease | Soraprazan | participant | 5.792.425 | 7 |
2013-08-01 | A new therapeutic antibody with a personalised medicine approach in cardiovascular disease | CARDIMMUN | participant | 5.995.080 | 5 |
2012-10-01 | New approach to treatment of the blinding disease Retinopathy of Prematurity (ROP) | PREVENTROP | participant | 5.990.236 | 10 |